USP7 and neoplasm: USP7 inhibition in fibroblasts leads to a significant decrease in tumour neoangiogenesis, modulation of the tumour immune microenvironment, tumour growth inhibition and striking tumour responses in syngeneic models when dosed in combination with immune checkpoint inhibitors (ICIs), resulting in significantly improved survival.